Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England

Nature. 2021 May;593(7858):266-269. doi: 10.1038/s41586-021-03470-x. Epub 2021 Mar 25.

Abstract

The SARS-CoV-2 lineage B.1.1.7, designated variant of concern (VOC) 202012/01 by Public Health England1, was first identified in the UK in late summer to early autumn 20202. Whole-genome SARS-CoV-2 sequence data collected from community-based diagnostic testing for COVID-19 show an extremely rapid expansion of the B.1.1.7 lineage during autumn 2020, suggesting that it has a selective advantage. Here we show that changes in VOC frequency inferred from genetic data correspond closely to changes inferred by S gene target failures (SGTF) in community-based diagnostic PCR testing. Analysis of trends in SGTF and non-SGTF case numbers in local areas across England shows that B.1.1.7 has higher transmissibility than non-VOC lineages, even if it has a different latent period or generation time. The SGTF data indicate a transient shift in the age composition of reported cases, with cases of B.1.1.7 including a larger share of under 20-year-olds than non-VOC cases. We estimated time-varying reproduction numbers for B.1.1.7 and co-circulating lineages using SGTF and genomic data. The best-supported models did not indicate a substantial difference in VOC transmissibility among different age groups, but all analyses agreed that B.1.1.7 has a substantial transmission advantage over other lineages, with a 50% to 100% higher reproduction number.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Age Distribution
  • Aged
  • Aged, 80 and over
  • Basic Reproduction Number
  • COVID-19 / diagnosis
  • COVID-19 / epidemiology
  • COVID-19 / transmission*
  • COVID-19 / virology*
  • Child
  • Child, Preschool
  • England / epidemiology
  • Evolution, Molecular
  • Genome, Viral / genetics
  • Humans
  • Infant
  • Infant, Newborn
  • Middle Aged
  • Phylogeny*
  • SARS-CoV-2 / classification*
  • SARS-CoV-2 / genetics
  • SARS-CoV-2 / isolation & purification
  • SARS-CoV-2 / pathogenicity*
  • Spike Glycoprotein, Coronavirus / analysis
  • Spike Glycoprotein, Coronavirus / genetics
  • Time Factors
  • Young Adult

Substances

  • Spike Glycoprotein, Coronavirus
  • spike protein, SARS-CoV-2